Lee Jinhwa, Song Kwang-Seop, Kang Jahyo, Lee Suk Ho, Lee Junwon
Central Research Laboratories, Green Cross Corporation, 303 Bojeong-Dong, Giheung-Gu, Yongin, Gyeonggi-Do, 446-770, Republic of Korea.
Curr Top Med Chem. 2009;9(6):564-96. doi: 10.2174/156802609788897853.
The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe, effective obesity drugs are commercially available at the present time. Only two drugs have been approved in the United States for the long-term treatment of obesity, sibutramine and orlistat. However, these drugs are minimally effective and have significant side effects, which are likely inhibit their use. Therefore, there is a huge opportunity to make a significant impact on the lives of obese people through the discovery and development of additional pharmacotherapeutic options. In this review article, the authors focus on selected trends in medicinal chemistry and the approaches used to develop drugs for treating obesity.
受社会和经济变革的推动，超重和肥胖的患病率正在全球范围内以惊人的速度上升。此外，肥胖与主要疾病的发病机制相关，尤其是糖尿病和心血管疾病。然而，目前尚无令人满意的安全、有效的肥胖药物可供商业使用。在美国，仅有两种药物被批准用于肥胖症的长期治疗，即西布曲明和奥利司他。然而，这些药物效果甚微且有显著的副作用，这可能会限制它们的使用。因此，通过发现和开发更多的药物治疗选择，对肥胖人群的生活产生重大影响存在巨大的机会。在这篇综述文章中，作者重点关注药物化学的选定趋势以及用于开发治疗肥胖症药物的方法。
